Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMX0035 versus placebo in adults with amyotrophic lateral sclerosis
NL-OMON54389Phase 3Recruiting
- Sponsor
- Amylyx Pharmaceuticals
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sodium phenylbutyrate in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Amylyx Pharmaceuticals. Primary endpoint: Disease progression over 48 weeks. Started Dec 2021; status: recruiting.
02
Drugs
sodium phenylbutyrate
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON54389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54389.